# Neurogene Inc.: financial statements, quarterly

NGNE · Nasdaq · CIK 1404644 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ngne.md) · [Financials](/companies/ngne/financials.md) · [Filings](/companies/ngne/filings.md) · [Insiders](/companies/ngne/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ngne/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001404644-24-000104.md) | [0.0 d](/filings/0001404644-25-000012.md) | not reported | [0.9](/filings/0001404644-25-000081.md) | [0.0](/filings/0001404644-25-000101.md) | [0.0 d](/filings/0001404644-26-000019.md) | not reported | [0.0](/filings/0001404644-25-000081.md) | [0.0](/filings/0001404644-25-000101.md) | [0.0 d](/filings/0001404644-26-000019.md) | not reported | not reported |
| Research and development | $m | [11.6](/filings/0001404644-24-000104.md) | [12.2 d](/filings/0001404644-25-000012.md) | [13.5](/filings/0001404644-25-000041.md) | [15.7](/filings/0001404644-25-000081.md) | [16.3](/filings/0001404644-25-000101.md) | [15.3 d](/filings/0001404644-26-000019.md) | [17.8](/filings/0001404644-26-000037.md) | [19.4](/filings/0001404644-26-000059.md) | [17.2](/filings/0001404644-25-000101.md) | [20.6 d](/filings/0001404644-26-000019.md) | [25.2](/filings/0001404644-26-000037.md) | [25.5](/filings/0001404644-26-000059.md) |
| Operating income | $m | [(15.2)](/filings/0001404644-24-000104.md) | [(14.7) d](/filings/0001404644-25-000012.md) | [(18.8)](/filings/0001404644-25-000041.md) | [(20.1)](/filings/0001404644-25-000081.md) | [(22.2)](/filings/0001404644-25-000101.md) | [(21.5) d](/filings/0001404644-26-000019.md) | [(25.9)](/filings/0001404644-26-000037.md) | [(26.1)](/filings/0001404644-26-000059.md) | [(23.8)](/filings/0001404644-25-000101.md) | [(27.5) d](/filings/0001404644-26-000019.md) | [(33.3)](/filings/0001404644-26-000037.md) | [(36.7)](/filings/0001404644-26-000059.md) |
| Interest expense | $m | [0.0](/filings/0001404644-24-000104.md) | [0.0 d](/filings/0001404644-24-000020.md) | [0.0](/filings/0001404644-24-000057.md) | [0.0](/filings/0001404644-25-000081.md) | [0.0](/filings/0001404644-25-000101.md) | [0.0 d](/filings/0001404644-26-000019.md) | [0.0](/filings/0001404644-26-000037.md) | [0.0](/filings/0001404644-26-000059.md) | [0.0](/filings/0001404644-25-000101.md) | [0.0 d](/filings/0001404644-26-000019.md) | [0.0](/filings/0001404644-26-000037.md) | [0.0](/filings/0001404644-26-000059.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(14.6)](/filings/0001404644-24-000104.md) | [2.4 d](/filings/0001404644-25-000012.md) | [(16.9)](/filings/0001404644-25-000101.md) | [(18.5)](/filings/0001404644-25-000101.md) | [(20.2)](/filings/0001404644-25-000101.md) | [(19.5) d](/filings/0001404644-26-000019.md) | [(22.6)](/filings/0001404644-26-000059.md) | [(22.0)](/filings/0001404644-26-000059.md) | [(21.0)](/filings/0001404644-25-000101.md) | [(24.7) d](/filings/0001404644-26-000019.md) | [(30.9)](/filings/0001404644-26-000059.md) | [(34.5)](/filings/0001404644-26-000059.md) |
| Diluted EPS | $ per share | [(32.67)](/filings/0001404644-24-000104.md) | not reported | [(1.00)](/filings/0001404644-25-000041.md) | [(1.09)](/filings/0001404644-25-000081.md) | [(1.19)](/filings/0001404644-25-000101.md) | not reported | [(1.08)](/filings/0001404644-26-000037.md) | [(1.05)](/filings/0001404644-26-000059.md) | [(0.99)](/filings/0001404644-25-000101.md) | not reported | [(1.39)](/filings/0001404644-26-000037.md) | [(1.53)](/filings/0001404644-26-000059.md) |
| Basic EPS | $ per share | [(32.67)](/filings/0001404644-24-000104.md) | not reported | [(1.00)](/filings/0001404644-25-000041.md) | [(1.09)](/filings/0001404644-25-000081.md) | [(1.19)](/filings/0001404644-25-000101.md) | not reported | [(1.08)](/filings/0001404644-26-000037.md) | [(1.05)](/filings/0001404644-26-000059.md) | [(0.99)](/filings/0001404644-25-000101.md) | not reported | [(1.39)](/filings/0001404644-26-000037.md) | [(1.53)](/filings/0001404644-26-000059.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [25.2](/filings/0001628280-23-038797.md) | [148](/filings/0001404644-25-000012.md) | [150](/filings/0001404644-24-000057.md) | [111](/filings/0001404644-24-000086.md) | [66.6](/filings/0001404644-24-000104.md) | [137](/filings/0001404644-26-000019.md) | [70.8](/filings/0001404644-25-000041.md) | [58.8](/filings/0001404644-25-000081.md) | [71.0](/filings/0001404644-25-000101.md) | [104](/filings/0001404644-26-000059.md) | [124](/filings/0001404644-26-000037.md) | [112](/filings/0001404644-26-000059.md) |
| Current assets | $m | [79.9](/filings/0001628280-23-038797.md) | [200](/filings/0001404644-25-000012.md) | [174](/filings/0001404644-24-000057.md) | [159](/filings/0001404644-24-000086.md) | [144](/filings/0001404644-24-000104.md) | [316](/filings/0001404644-26-000019.md) | [296](/filings/0001404644-25-000041.md) | [279](/filings/0001404644-25-000081.md) | [271](/filings/0001404644-25-000101.md) | [272](/filings/0001404644-26-000059.md) | [247](/filings/0001404644-26-000037.md) | [229](/filings/0001404644-26-000059.md) |
| Total assets | $m | [89.6](/filings/0001628280-23-038797.md) | [223](/filings/0001404644-25-000012.md) | [195](/filings/0001404644-24-000057.md) | [180](/filings/0001404644-24-000086.md) | [164](/filings/0001404644-24-000104.md) | [336](/filings/0001404644-26-000019.md) | [315](/filings/0001404644-25-000041.md) | [297](/filings/0001404644-25-000081.md) | [288](/filings/0001404644-25-000101.md) | [289](/filings/0001404644-26-000059.md) | [263](/filings/0001404644-26-000037.md) | [244](/filings/0001404644-26-000059.md) |
| Current liabilities | $m | [5.2](/filings/0001628280-23-038797.md) | [23.0](/filings/0001404644-25-000012.md) | [11.8](/filings/0001404644-24-000057.md) | [13.1](/filings/0001404644-24-000086.md) | [15.8](/filings/0001404644-24-000104.md) | [15.2](/filings/0001404644-26-000019.md) | [14.1](/filings/0001404644-25-000041.md) | [15.4](/filings/0001404644-25-000081.md) | [14.7](/filings/0001404644-25-000101.md) | [16.4](/filings/0001404644-26-000059.md) | [18.9](/filings/0001404644-26-000037.md) | [21.5](/filings/0001404644-26-000059.md) |
| Total liabilities | $m | [14.4](/filings/0001628280-23-038797.md) | [36.5](/filings/0001404644-25-000012.md) | [24.6](/filings/0001404644-24-000057.md) | [24.8](/filings/0001404644-24-000086.md) | [26.7](/filings/0001404644-24-000104.md) | [25.4](/filings/0001404644-26-000019.md) | [23.5](/filings/0001404644-25-000041.md) | [24.1](/filings/0001404644-25-000081.md) | [22.3](/filings/0001404644-25-000101.md) | [23.7](/filings/0001404644-26-000059.md) | [25.4](/filings/0001404644-26-000037.md) | [27.2](/filings/0001404644-26-000059.md) |
| Shareholders' equity | $m | [(183)](/filings/0001404644-24-000104.md) | [186](/filings/0001404644-26-000019.md) | [171](/filings/0001404644-25-000101.md) | [155](/filings/0001404644-25-000101.md) | [137](/filings/0001404644-25-000101.md) | [310](/filings/0001404644-26-000059.md) | [292](/filings/0001404644-26-000059.md) | [273](/filings/0001404644-26-000059.md) | [266](/filings/0001404644-25-000101.md) | [265](/filings/0001404644-26-000059.md) | [238](/filings/0001404644-26-000059.md) | [217](/filings/0001404644-26-000059.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.6) d](/filings/0001404644-24-000104.md) | [(17.0) d](/filings/0001404644-25-000012.md) | [(21.7)](/filings/0001404644-25-000041.md) | [(15.9) d](/filings/0001404644-25-000081.md) | [(15.6) d](/filings/0001404644-25-000101.md) | [(17.5) d](/filings/0001404644-26-000019.md) | [(20.8)](/filings/0001404644-26-000037.md) | [(19.5) d](/filings/0001404644-26-000059.md) | [(19.5) d](/filings/0001404644-25-000101.md) | [(17.4) d](/filings/0001404644-26-000019.md) | [(26.1)](/filings/0001404644-26-000037.md) | [(23.8) d](/filings/0001404644-26-000059.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001404644-24-000104.md) | [0.1 d](/filings/0001404644-25-000012.md) | [0.1](/filings/0001404644-25-000041.md) | [0.5 d](/filings/0001404644-25-000081.md) | [0.2 d](/filings/0001404644-25-000101.md) | [0.1 d](/filings/0001404644-26-000019.md) | [0.8](/filings/0001404644-26-000037.md) | [0.1 d](/filings/0001404644-26-000059.md) | [0.1 d](/filings/0001404644-25-000101.md) | [0.1 d](/filings/0001404644-26-000019.md) | [0.3](/filings/0001404644-26-000037.md) | [0.4 d](/filings/0001404644-26-000059.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [11.1](/filings/0001628280-23-038797.md) | [55.4](/filings/0001628280-23-016425.md) | [0.4](/filings/0001404644-24-000086.md) | [0.4](/filings/0001404644-24-000104.md) | [16.9](/filings/0001404644-25-000041.md) | [16.9](/filings/0001404644-25-000081.md) | [17.0](/filings/0001404644-25-000101.md) | [21.0](/filings/0001404644-26-000037.md) | [21.1](/filings/0001404644-26-000059.md) | [21.2](/filings/0001404644-25-000101.md) | [22.3](/filings/0001404644-26-000037.md) | [22.6](/filings/0001404644-26-000059.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 20,011,382 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001404644-26-000059.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.